Cormedix Leads Limited Pipeline For US FDA’s LPAD Pathway
Executive Summary
Cormedix prepares NDA submission for Neutrolin for prevention of catheter-related blood stream infections, aiming to become the third approval under the US FDA’s Limited Population Pathway.